129 related articles for article (PubMed ID: 38787543)
21. Net Spending On Retail Specialty Drugs Grew Rapidly, Especially For Private Insurance And Medicare Part D.
Hill SC; Miller GE; Ding Y
Health Aff (Millwood); 2020 Nov; 39(11):1970-1976. PubMed ID: 33136501
[TBL] [Abstract][Full Text] [Related]
22. Federal and Individual Spending on the 10 Costliest Medications in Medicare Part D from 2011 to 2015.
Watanabe JH; Chau DL; Hirsch JD
J Am Geriatr Soc; 2018 Aug; 66(8):1621-1624. PubMed ID: 29972589
[TBL] [Abstract][Full Text] [Related]
23. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
Rosenberg ME; Rosenberg SP
JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
[TBL] [Abstract][Full Text] [Related]
24. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
[TBL] [Abstract][Full Text] [Related]
25. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.
Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA
JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701
[TBL] [Abstract][Full Text] [Related]
26. Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments.
Arambadjis Y; Butler M; Huckfeldt P; Schondelmeyer S
Res Social Adm Pharm; 2020 Sep; 16(9):1290-1293. PubMed ID: 31147206
[TBL] [Abstract][Full Text] [Related]
27. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
28. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
29. Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid.
McCormick N; Wallace ZS; Sacks CA; Hsu J; Choi HK
Arthritis Rheumatol; 2020 Feb; 72(2):234-241. PubMed ID: 31609057
[TBL] [Abstract][Full Text] [Related]
30. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
31. Has The Era Of Slow Growth For Prescription Drug Spending Ended?
Aitken M; Berndt ER; Cutler D; Kleinrock M; Maini L
Health Aff (Millwood); 2016 Sep; 35(9):1595-603. PubMed ID: 27605638
[TBL] [Abstract][Full Text] [Related]
32. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
Sacks CA; Lee CC; Kesselheim AS; Avorn J
JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
[TBL] [Abstract][Full Text] [Related]
33. The influence of Medicare Part D on the list pricing of brand drugs.
Ippolito BN; Levy JF
Health Serv Res; 2023 Aug; 58(4):948-952. PubMed ID: 36737865
[TBL] [Abstract][Full Text] [Related]
34. A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?
San-Juan-Rodriguez A; Gellad WF; Shrank WH; Good CB; Hernandez I
J Manag Care Spec Pharm; 2021 May; 27(5):565-573. PubMed ID: 33908276
[No Abstract] [Full Text] [Related]
35. Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20.
Rome BN; Patel AN; Kesselheim AS
Health Aff (Millwood); 2023 Jun; 42(6):770-778. PubMed ID: 37276474
[TBL] [Abstract][Full Text] [Related]
36. Coverage for hepatitis C drugs in Medicare Part D.
Jung JK; Feldman R; Cheong C; Du P; Leslie D
Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
[TBL] [Abstract][Full Text] [Related]
37. Specialty Drug Price Trends in the Federal 340B Drug Discount Program.
Lee CH; Chang J; McCombs J
J Manag Care Spec Pharm; 2019 Feb; 25(2):178-187. PubMed ID: 30698090
[TBL] [Abstract][Full Text] [Related]
38. The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act.
Bonakdar Tehrani A; Carroll NV
Appl Health Econ Health Policy; 2017 Aug; 15(4):513-520. PubMed ID: 28224469
[TBL] [Abstract][Full Text] [Related]
39. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
Gross DJ; Schondelmeyer SW; Raetzman SO
Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications.
Mattingly TJ; Anderson GF; Levy JF
JAMA Health Forum; 2023 Jun; 4(6):e231317. PubMed ID: 37294584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
